Results 101 to 110 of about 41,070 (225)

Serum Survivin Increases in Prolactinoma

Journal of Clinical Medicine Research, 2015
Prolactinoma is the most common adult pituitary adenoma. Survivin is a member of the family of inhibitors of apoptosis proteins. Its expression is observed in many tumors. Survivin expression has shown in prolactinoma tissue before but no study exists showing serum survivin level. The aim of the present study was to investigate serum survivin levels in
Dellal, Fatma Dilek, Niyazoğlu, Mutlu, Gorar, Süheyla, Ademoğlu, Esranur, Candan, Zehra, Bekdemir, Handan, Hacıoğlu, Yalçın, Kaya, Fatih Öner   +7 more
openaire   +4 more sources

Interactions Between E3 Ubiquitin Ligases and Deubiquitinases in AKT Regulation: Implications in Skeletal Muscle Homeostasis

Cell Biochemistry and Function, Volume 44, Issue 9, September 2026.
ABSTRACT AKT (protein kinase B, PKB) coordinates the balance between anabolic and catabolic signaling in skeletal muscle through distinct ubiquitin chain types. Some E3 ubiquitin ligases (E3s) and deubiquitinases (DUBs) form stable binary complexes via non‐catalytic interfaces, adding a regulatory layer unavailable to either enzyme alone.
Rajesh Dabur
wiley   +1 more source

Reactive Oxygen Species in Breast Cancer: From Redox Dysregulation to ROS‐Responsive Therapeutics

Cell Biochemistry and Function, Volume 44, Issue 9, September 2026.
ABSTRACT Breast cancer is the most frequently diagnosed malignancy among women worldwide, with 2.3 million new cases and approximately 670,000 deaths reported in 2022 alone. Despite advances in therapy, metastasis and acquired drug resistance remain major clinical challenges.
Marija Nikolovska, Radoslav Stojchevski, Aleksandar Eftimov, Mitko Mladenov, Dimiter Avtanski, Nikola Hadzi‐Petrushev   +5 more
wiley   +1 more source

Venetoclax for elderly patients with acute myeloid leukaemia unfit for intensive chemotherapy: Prospects, resistance mechanisms and management strategies

Clinical and Translational Medicine, Volume 16, Issue 9, September 2026.
Resistance to venetoclax has become a critical bottleneck limiting its long‐term clinical benefits. A thorough understanding of the underlying resistance mechanisms and the development of novel strategies to overcome resistance are central to improving survival outcomes in elderly AML patients. Abstract To date, the treatment of acute myeloid leukaemia
Jinlin Zhang, Jile Liu, Mohan Zhao, Xiaoyu Zhang, Linlin Liu, Mengnan Li, Changze Cao, Rui Zhang, Mingfeng Zhao   +8 more
wiley   +1 more source

Icariside II in Neurological Disorders: Mechanistic Insights Into Alzheimer's Disease, Cerebral Ischemia and Parkinson's Disease

Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 9, September 2026.
The graphical abstract represents the underlying neuroprotective potential of ICS II against Alzheimer's disease, Cerebral ischemia and Parkinson disease. ICS II downregulates ROS production, inflammation, mitochondrial dysfunction and apoptosis along with regulating their key signalling pathways.
Ashutosh Solanki, Khushi Sharma, Jagrati Jain, Niraj Kumar Singh, Praveen T. Krishnamurthy   +4 more
wiley   +1 more source

Dual‐Drug‐Loaded Liposomes: Design Strategies, Mechanistic Insights, and Therapeutic Applications in Cancer

MedComm – Biomaterials and Applications, Volume 5, Issue 3, September 2026.
Dual‐drug‐loaded liposomes enable the simultaneous delivery of hydrophilic and hydrophobic therapeutics to tumors, enhancing anticancer efficacy and overcoming multidrug resistance. Through rational formulation design and surface functionalization, these systems improve tumor targeting, modulate efflux mechanisms and EMT, and achieve synergistic ...
Neelam Sinha, Rohan Chand Sahu, Rohit Patil, Dinesh Kumar, Ashish Kumar Agrawal   +4 more
wiley   +1 more source

Nanoformulated cell-penetrating survivin mutant and its dual actions

, 2014
Bhasker Sriramoju, Rupinder K Kanwar, Jagat R Kanwar Nanomedicine Laboratory of Immunology and Molecular Biomedical Research (NLIMBR), School of Medicine, Faculty of Health, Deakin University, Geelong, Australia Abstract: In this study, we investigated
Sriramoju B, Kanwar RK, Kanwar JR
core  

Cyclins and Cyclin‐Dependent Kinases: Structure, Biological Functions, and Innovative Targeting Strategies in Cancer

MedComm, Volume 7, Issue 9, September 2026.
This work synthesizes recent insights into the pathological roles of cyclins and cyclin‐dependent kinases (CDKs) across human cancers, highlights state‐of‐the‐art innovative approaches (especially targeted degradation and redistribution of CDK/cyclin proteins) for cancer therapy, and outlines future directions for CDK/cyclin‐related biomedical research.
Suya Zheng, Zhipeng Shen, Yuanfang Wu, Xingze Huang, Zhongyuan Zhang, Jiangyu Liu, Qichun Wei, Wenhao Chen, Ye Chen, Liang Xu   +9 more
wiley   +1 more source

Correlation Between Tumor Budding and Survivin Expression in Colorectal Cancer [PDF]

Guangping Zhang, Qingzhong Min Department of Pathology, Ya’an People’s Hospital, Ya’an, Sichuan, People’s Republic of ChinaCorrespondence: Qingzhong Min, Department of Pathology, Ya’an People’s Hospital, Ya’an, Sichuan, People’s Republic of China, Tel ...
Zhang G, Min Q
core  

Artificial Intelligence Integration With Nanotechnology for Cancer Therapy

MedComm, Volume 7, Issue 9, September 2026.
AI‐enabled nanotechnology provides a continuous learning framework for cancer therapy by integrating nanomaterial design, biological interactions, tumor delivery, clinical data, and therapeutic feedback to support predictive design, patient‐aware optimization, and improved translational decision‐making.
Shengbin Liu, Zhi Liu, Haixing Shi, Chengyi Wei, Ruijie Zhang, Xiangrong Song   +5 more
wiley   +1 more source